NTHL1 and neoplasm: A previous study by Grolleman et al. has shown that the mutation spectrum in biallelic NTHL1 carriers can predispose to a wider tumour spectrum than just affecting the colon and includes tumours of the breast, endometrial, head and neck squamous cell carcinoma, meningioma, thyroid and urothelial cell cancers [7].